Literature DB >> 11487036

The epidemiology of venous thromboembolism in the community.

J A Heit1, M D Silverstein, D N Mohr, T M Petterson, C M Lohse, W M O'Fallon, L J Melton.   

Abstract

The incidence of venous thromboembolism exceeds 1 per 1000; over 200,000 new cases occur in the United States annually. Of these, 30% die within 30 days; one-fifth suffer sudden death due to pulmonary embolism. Despite improved prophylaxis, the incidence of venous thromboembolism has been constant since 1980. Independent risk factors for venous thromboembolism include increasing age, male gender, surgery, trauma, hospital or nursing home confinement, malignancy, neurologic disease with extremity paresis, central venous catheter/transvenous pacemaker, prior superficial vein thrombosis, and varicose veins; among women, risk factors include pregnancy, oral contraceptives, and hormone replacement therapy. About 30% of surviving cases develop recurrent venous thromboembolism within ten years. Independent predictors for recurrence include increasing age, obesity, malignant neoplasm, and extremity paresis. About 28% of cases develop venous stasis syndrome within 20 years. To reduce venous thromboembolism incidence, improve survival, and prevent recurrence and complications, patients with these characteristics should receive appropriate prophylaxis.

Entities:  

Mesh:

Year:  2001        PMID: 11487036

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  93 in total

1.  British Thoracic Society guidelines for the management of suspected acute pulmonary embolism.

Authors: 
Journal:  Thorax       Date:  2003-06       Impact factor: 9.139

2.  Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux.

Authors:  Kakunoshin Yoshida; Hideo Wada; Masahiro Hasegawa; Hiroki Wakabayashi; Takeshi Matsumoto; Yuji Shimokariya; Katsura Noma; Norikazu Yamada; Atsumasa Uchida; Tsutomu Nobori; Akihiro Sudo
Journal:  Int J Hematol       Date:  2012-01-21       Impact factor: 2.490

3.  Using multiple sources of data for surveillance of postoperative venous thromboembolism among surgical patients treated in Department of Veterans Affairs hospitals, 2005-2010.

Authors:  Richard E Nelson; Scott D Grosse; Norman J Waitzman; Junji Lin; Scott L DuVall; Olga Patterson; James Tsai; Nimia Reyes
Journal:  Thromb Res       Date:  2015-01-26       Impact factor: 3.944

4.  Neighborhood deprivation and hospitalization for venous thromboembolism in Sweden.

Authors:  Bengt Zöller; Xinjun Li; Jan Sundquist; Kristina Sundquist
Journal:  J Thromb Thrombolysis       Date:  2012-10       Impact factor: 2.300

Review 5.  The post-thrombotic syndrome: the forgotten morbidity of deep venous thrombosis.

Authors:  Susan R Kahn
Journal:  J Thromb Thrombolysis       Date:  2006-02       Impact factor: 2.300

Review 6.  Bioengineered in vitro models of thrombosis: methods and techniques.

Authors:  Yu Shrike Zhang; Rahmi Oklu; Hassan Albadawi
Journal:  Cardiovasc Diagn Ther       Date:  2017-12

7.  Plasmin inhibition increases MMP-9 activity and decreases vein wall stiffness during venous thrombosis resolution.

Authors:  Nicholas A Dewyer; Vikram Sood; Erin M Lynch; Catherine E Luke; Gilbert R Upchurch; Thomas W Wakefield; Steven Kunkel; Peter K Henke
Journal:  J Surg Res       Date:  2007-06-14       Impact factor: 2.192

8.  Physician compliance with outpatient oral anticoagulant guidelines in Auvergne, France.

Authors:  Marc Ruivard; Christine Berger; Abdellaziz Achaibi; Claude Campagne; Pierre Philippe
Journal:  J Gen Intern Med       Date:  2003-11       Impact factor: 5.128

9.  Incidence of venous thromboembolic events among nursing home residents.

Authors:  Josephine P Gomes; Wassim H Shaheen; Son V Truong; Edward F Brown; Brent W Beasley; Byron J Gajewski
Journal:  J Gen Intern Med       Date:  2003-11       Impact factor: 5.128

Review 10.  Current state of anticoagulants to treat deep venous thrombosis.

Authors:  Timothy Vo; Sara Vazquez; Matthew T Rondina
Journal:  Curr Cardiol Rep       Date:  2014-03       Impact factor: 2.931

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.